Hong Kong Biotech Stocks Decline as BeiGene and WuXi Biologics Lead Losses
Hong Kong's biotech sector experienced a downturn with significant declines in key stocks. According to Jin10, BeiGene (06160.HK) saw a drop of over 9%, while WuXi Biologics (02269.HK) fell more than 7%. Other companies, including WuXi AppTec (02359.HK) and Junshi Biosciences (01877.HK), also followed the downward trend. The sector's performance reflects broader market challenges impacting the innovative drug segment.
Source: CoinLive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments